Login with Linked

Follow us on

Link Linkedin Youtube

Iomervu

Iomervu is an injectable contrast agent for CT scans and angiography in adults and children. It enhances artery and organ imaging by providing clear, safe visualization of vascular structures.

Molecule Details :

  • Molecule Name :

    Iomeprol

  • Innovator :

    BRACCO DIAGNOSTICS INC

  • Approval Date :

    27-Nov-24

  • NCE-1 Date :

    27-Nov-28

  • NCE Date :

    27-Nov-29

  • Dosage Form :

    Intra-Arterial And Intravenous

  • Strength :

    15gm/50ml, 17.5gm/50ml, 20gm/50ml, 25gm/100ml, 30gm/100ml, 35gm/100ml, 40gm/100ml, 60gm/150ml and 45gm/150ml

  • Therapeutic Category :

    Diagnostic Agents

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA

  • 2026 :

    NA

  • 2027 :

    NA

  • 2028 :

    NA

  • 2029 :

    NA

  • 2030 :

    NA

  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?